Stocktoria
ASSEMBLY BIOSCIENCES, INC. ASMB
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2010-12-17
ASSEMBLY BIOSCIENCES, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $72.3M | $28.5M | $7.2M | $0 | $6.3M |
| R&D expense | $64.8M | $55.9M | $48.9M | $70.0M | $68.5M |
| Operating income | -$12.1M | -$45.4M | -$64.6M | -$94.1M | -$132.7M |
| Income tax | $0 | $330,000 | $33,000 | $0 | -$2.5M |
| Net income | -$6.1M | -$40.2M | -$61.2M | -$93.1M | -$129.9M |
| EPS (diluted) | $-0.55 | $-6.69 | $-13.38 | $-23.08 | $-3.00 |
| Operating cash flow | -$41.1M | -$51.1M | $22.7M | -$84.5M | -$93.4M |
| Free cash flow | -$41.2M | -$51.1M | $22.5M | -$84.6M | -$96.5M |
| Cash & equivalents | $58.5M | $38.3M | $19.8M | $52.4M | $45.6M |
| Total assets | $257.6M | $119.2M | $136.8M | $101.8M | $191.1M |
| Total liabilities | $50.8M | $85.8M | $95.7M | $19.1M | $22.1M |
| Shareholders' equity | $206.8M | $33.4M | $41.1M | $82.7M | $168.9M |
Source: SEC EDGAR filings · CIK 0001426800 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.